ApoE alleles and tau markers in patients with different levels of cognitive impairment

Archives of Medical Research

Volumn 36, Issue 5, 2005, Pages 474-479

  Lavados, Manuel ^a   Farías, Gustavo ^b   Rothhammer, Francisco ^a   Guillon, Marta ^a   Mujica, Maria C ^a   Maccioni, Cristóbal ^b   Maccioni, Ricardo B ^a,b  

^a UNIVERSITY OF CHILE   (Chile)

^b UNIVERSITY OF CHILE   (Chile)

Author keywords

Alzheimer's disease; Apolipoprotein E; Cerebrospinal fluid; Mild cognitive impairment; Tau protein

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN EPSILON 2; APOLIPOPROTEIN EPSILON 3; APOLIPOPROTEIN EPSILON 4; MONOCLONAL ANTIBODY; TAU PROTEIN; UNCLASSIFIED DRUG;

AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; BLOOD SAMPLING; CEREBROSPINAL FLUID ANALYSIS; COGNITIVE DEFECT; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MARKER GENE; POLYMERASE CHAIN REACTION; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; SENILITY; STATISTICAL SIGNIFICANCE;

AGED; ALLELES; APOLIPOPROTEINS E; COGNITION DISORDERS; FEMALE; GENETIC MARKERS; GENOTYPE; HUMANS; LONGITUDINAL STUDIES; MALE; PHOSPHORYLATION; PROTEIN ISOFORMS; TAU PROTEINS;

EID: 23744505013     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2005.03.036     Document Type: Article

References (34)

1. Maccioni RB, Muñoz JP, Barbeito L. The molecular bases of Alzheimer's disease and other neurodegenerative disorders. Arch Med Res 2001;32:367-381.
2. R. Katzman, and P. Fox The worldwide impact of dementia. Projections of prevalence and costs R. Mayeux Y. Christen Epidemiology of Alzheimer's Disease: From Gene to Prevention 1999 Springer Verlag New York 1 17
3. E.M. Mandelkow, and E. Mandelkow Tau in Alzheimer's disease Trends Cell Biol 8 1998 425 427
4. N. Andreasen, E. Vanmechelen, H. Vanderstichele, P. Davidsson, and K. Blennow Cerebrospinal fluid levels of total-tau, phospho-tau and Aβ42 predicts development of Alzheimer's disease in patients with mild cognitive impairment Acta Neurol Scand 179 Suppl 2003 47 51
5. H. Arai, Y. Nakagawa, M. Kosaka, T. Higuchi, N. Matsui, M. Okamura, H. Tashiro, and H. Sasaki Elevated cerebrospinal fluid tau protein level as a predictor of dementia in memory-impaired individuals Alzheimer Res 3 1997 211 213
6. K. Blennow, A. Wallin, H. Agren, C. Spenger, J. Siegfried, and E. Vanmechelen Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol 26 1995 231 245
7. A.L. Guillozet, S. Wintraub, D.C. Mash, and M. Mesulam Neurofibrillary tangles, amyloid and memory in aging and mild cognitive impairment Arch Neurol 60 2003 729 736
8. N. Andreasen, C. Hesse, P. Davidsson, L. Minthon, A. Wallin, B. Winblad, H. Vanderstichele, E. Vanmechelen, and K. Blennow Cerebrospinal fluid beta-amyloid (1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease Arch Neurol 56 1999 673 680
9. H. Hampel, A. Goernitz, and K. Buerger Advances in the development of biomarkers for Alzheimer's disease: from CSF total tau and A beta (1-42) proteins to phosphorylated tau protein Brain Res Bull 61 2003 243 253
10. M. Herrmann, S. Golombowski, K. Krauchi, P. Frey, C. Mourton-Gilles, C. Hulette, C. Rosenberg, F. Muller-Spahn, and C. Hock ELISA-quantitation of phosphorylated tau protein in the Alzheimer's disease brain Eur Neurol 42 1999 205 210
11. R.B. Maccioni, M. Lavados, C.B. Maccioni, and A. Mendoza Biological markers of Alzheimer's disease and mild cognitive impairment Curr Alzheimer Res 1 2004 307 314
12. J.T. Zambrano, M.T. Egaña, R.B. Núñez, R.B. Maccioni, and C. González-Billault Oxidative stress promotes tau dephosphorylation in neuronal cells. Role of Cdk5 and PP1 Free Rad Res Med 36 2003 1393 1402
13. M.A. Smith, P.L. Harris, L.M. Sayre, and G. Perry Iron accumulation in Alzheimer disease is a source of redox-generated free radicals Proc Natl Acad Sci USA 94 1997 9866 9868
14. J.T. Egaña, C. Zambrano, M.T. Nuñez, C. Gonzalez-Billault, and R.B. Maccioni Iron-induced oxidative stress modify tau phosphorylation patterns in hippocampal cell cultures Biometals 16 2003 215 223
15. R. Quintanilla, D. Orellana, C. Gonzalez-Billault, and R.B. Maccioni Interleukin-6 induces Alzheimer's type phosphorylation of tau by the cdk5/p35 pathway Exp Cell Res 295 2003 245 247
16. A.S. Lanzrein, C.M. Johnston, V.H. Perry, K.A. Jobst, E.M. King, and A.D. Smith Longitudinal study of inflammatory factors in serum, CSF and brain tissue in Alzheimer's disease: IL-1beta, IL-6 receptor antagonist, TNF alpha, the soluble TNF receptors I and II, and alpha 1-antichymotripsin Alzheimer Dis Assoc Disord 12 1998 215 227
17. E. Saez, M. Pehar, M. Vargas, L. Barbeito, and R.B. Maccioni Astrocytic nitric oxide triggers tau hyperphosphorylation in hippocampal neurons In Vivo 18 2004 275 280
18. T. Abe, H. Tohgi, C. Isobe, T. Murata, and C. Sato Remarkable increase in the concentration of 8-hydroxyguanosine in cerebrospinal fluid from patients with Alzheimer's disease J Neurosci Res 70 2002 447 450
19. X. Huang, C.S. Atwood, M.A. Hartshorn, G. Multhaup, L.E. Goldstein, R.C. Scarpa, M.P. Cuajungco, D.N. Gray, J. Lim, R.D. Moir, R.E. Tanzi, and A.I. Bush The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction Biochemistry 38 1999 7609 7616
20. G. McKhann, D. Drachman, M. Folstein, R. Katzman, D. Price, and E.M. Stadlan Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group, Department of Health and Human Services Task Force on Alzheimer's Disease Neurology 34 1984 939 948
21. R.C. Petersen, G.E. Smith, S.C. Waring, R.J. Ivnik, E. Tangalos, and E. Kokmen Mild cognitive impairment. Clinical characterization and outcome Arch Neurol 56 1999 303 308
22. E. Daly, D. Zaitchik, M. Copeland, J. Schmahmann, J. Gunther, and M. Albert Predicting conversion to Alzheimer disease using standardized clinical information Arch Neurol 57 2000 675 680
23. C. Hughes, L. Berg, W. Danziger, L. Coben, and R. Martin A new clinical scale for the staging of dementia Br J Psychiatry 140 1982 566 572
24. L. Berg Clinical dementia rating (CDR) Psychopharmacol Bull 24 1988 637 639
25. Y.Y. Hu, S.S. He, X. Wang, Q.H. Duan, I. Grundke-Iqbal, K. Iqbal, and J. Wang Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients: an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay Am J Pathol 160 2002 1269 1278
26. P.R. Wenham, W.H. Price, G. Blandell, and E. Apolipoprotein Genotyping by one-stage PCR Lancet 337 1991 1158 1159
27. Q.S. Wang, L. Tian, Y.L. Huang, S. Qin, L.Q. He, and J.N. Zhou Olfactory identification and apolipoprotein E epsilon 4 allele in mild cognitive impairment Brain Res 951 2002 77 81
28. P. Celsis Age-related cognitive decline, mild cognitive impairment or preclinical Alzheimer's disease? Ann Med 32 2000 6 14
29. A. Alvarez, J.P. Muñoz, and R.B. Maccioni A Cdk5-p35 stable complex is involved in the beta-amyloid-induced deregulation of Cdk5 activity in hippocampal neurons Exp Cell Res 264 2001 266 274
30. T. Tapiola, M. Overmyer, M. Lehtovirta, S. Helisalmi, J. Ramberg, I. Alafuzoff, P. Riekkinen Sr., and H. Soininen The level of cerebrospinal fluid tau correlates with neurofibrillary tangles in Alzheimer's disease Neuroreport 8 1997 3961 3963
31. N. Itoh, H. Arai, K. Urakami, K. Ishiguro, H. Ohno, H. Hampel, K. Buerger, J. Wiltfang, M. Otto, H. Kretzschmar, H.J. Moeller, M. Imagawa, H. Kohno, K. Nakashima, S. Kuzuhara, H. Sasaki, and K. Imahori Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at Ser199 for the antemortem diagnosis of Alzheimer's disease Ann Neurol 50 2001 150 156
32. J. Neugroschl, and K.L. Davis Biological markers in Alzheimer disease Am J Geriatr Psychiatry 10 2002 660 677
33. T. Kampers, M. Pamgalos, H. Geerts, H. Wiech, and E. Mandelkow Assembly of paired helical filaments from mouse tau: implications for the neurofibrillary pathology in transgenic mouse models for Alzheimer's disease FEBS Lett 451 1999 39 44
34. A. Roses, A. Saunders, E.H. Corder, N. Risch, J. Haines, M. Pericak-Vance, S.H. Han, G. Einstein, C. Hulette, D. Schmechel, M. Goedert, K. Weisgraber, D. Huang, and W. Strittmatter Apolipoprotein E4 and E2 are susceptibility genes that affect the rate of Alzheimer disease expressivity J Cell Biochem 21B Suppl 1995 86